Appeal No. 1997-2743
Application No. 08/442,252
We reverse both rejections.
DISCUSSION
Rejection I
99m
Feld describes technetium -dioxime complexes for imaging the myocardium,
brain and hepatobiliary systems. The complexes “can be prepared by first combining
pertechnenate ion (in the form of a salt) with a vicinal dioxime . . . and a halogen . . . by
mixing a vicinal dioxime . . . , a source of halogen and a stabilizing agent.” Column 2, lines
15-20. The stabilizing agent, “a substance which is present during the preparation of the
complex . . . to prevent or retard an unwanted alteration of the physical state of the complex
and to increase the radiochemical purity of the labeled product,” can be “a primary,
secondary or tertiary amine (e.g., mono-, di- or trialkylamines, arylamines, arylalkylamines,
etc.), an amino alcohol, (e.g., alkanolamines), a diamine (e.g., alkanediamines, and amino
acid or ester thereof (e.g., glycine or an alkyl ester thereof), or a salt of any of the above
compounds, or "-, $- or (-cyclodextrin.” Column 2, lines 41-52. Finally, Feld describes
kits containing “a source of halogen, a dioxime . . . , a stabilizing agent and a reducing
99m
agent” (Column 3, lines 16-26) and also describes preparation of a Tc -dioxime complex
using a dioxime, (-cyclodextrin, sodium chloride, citric acid, a saturated aqueous solution
of stannous pyrrophosphate and sodium pertechnetate (Example 10, Method III).
Deutsch describes a brain perfusion imaging agent comprising a technetium99m
(III/II) center surrounded by six ligating moieties, some of which can be phosphines. In
3
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: November 3, 2007